GSK's vaccine arm lays claim to a major breakthrough on tuberculosis
GlaxoSmithKline’s vaccines group is heralding a “scientific breakthrough” on tuberculosis, pointing to hard evidence that an experimental jab of theirs can protect roughly half the people that get it.
TB is a fierce challenge in the vaccine field. The currently available vaccine BCG typically isn’t given to adults because it’s rarely effective in anyone other than children. So when GSK cites a 54% efficacy rate it may be far from perfect, but it represents a major leap forward in guarding against more than a million deaths a year from tuberculosis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
